|
|
 |
|
Viewing report
|
|
|
|
The Global Image Dermatology Drug Market, 2005-2012: High-Growth Opportunities in Aesthetic Medicine
Spectra Intelligence , Nov 2005, Pages: 158
Examines the global market for aesthetic dermatologicals and specialty physician-dispensed drugs to treat conditions associated with deficits in physical image and form. Drugs such as botulinum toxins, retinoids, acid peels, 5-alpha reductase and lipase inhibitors associated with cutaneous ageing, photodamage, pigmentation defects, alopecia, and the lipodermal disorders of obesity and gynoid lipodystrophy are critically discussed to provide a detailed analysis of the high-growth market sector estimated at US$1.8 billion in 2005 and forecast to increase by 114% to US$3.9 billion by 2012. The report includes insights for product extension and optimization, sales forecasts to 2012, and impact of late-stage pipeline drugs on the market. Therapy area forecasting and illustrative market data and analysis is also presented to gain insight into top-performing products and therapy areas.
Objectives of the Report Briefing
The objectives of this report are to provide a detailed analysis of the global image dermatology drug market. Included in this study are analyses of key therapy areas, R&D programs, and innovating companies and products. The report briefing also aims to expand knowledge of the therapeutic areas and to highlight the role of antiageing medicines and lifestyle drugs in an increasingly ageing world population. It is hoped that the reader will benefit from market forecasts, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to timulate growth and create new market opportunities.
Research Methodology
The contents of this report are derived from in-depth research-based surveys of the industry; communication with senior corporate executives; and proprietary analytical assessment tools.
Source material also comprises the following:
- Company information
- Personal communication
- Trade press articles
- News releases
- Internet-based research
- Library research
- Scientific periodicals
- Product information
- Market analyst data
- Public information datasets
- Conference proceedings
- Medical/pharma associations
REPORT HIGHLIGHTS AND KEY FINDINGS
- Dermatological drugs indicated for image dermatology account for a market valued at US$1.8 billion, which is predicted to increase 114% CAGR to 2012
- Critical analysis of alopecia, cutaneous ageing, photodamage, pigmentation deficits, obesity, cellulite and other lipodermal
conditions
- Comprehensive review of epidemiological, aetiological, and therapeutic data for 5 key therapy areas
- Analysis of over 20 marketed products and inclusion of 45 R&D candidates identified in preclinical to clinical stages of development
- Sales estimates (US$) to 2012 for critical therapy areas
- Strategic insights for life-cycle optimization and product development
- Evaluation of leading products and major competitors
- Emerging markets identified and sector analysis
- Trend analysis of industry events and activities over past 2 years
- Detailed R&D themes and clusters by therapy area
- Data generation on sector and market values between 2004 and 2012 and therapy forecasts by 2020 (US$)
q High revenue-yielding prospects identified with projected sales estimations
- R&D pipeline positioning for all therapy areas
- Market insights for product development and drug promotion
WHAT CAN I LEARN FROM THIS REPORT?
- What the main therapy areas are within the image dermatology field
- What the current treatment options are for alopecia, cutaneous ageing, photodamage, hyperand
hypopigmentation disorders, and obesity
- Who the market leaders are in the image dermatology field
- Which premarket drugs are identified as potential blockbusters
- What factors are involved in driving the aesthetic dermatology market
- What the sales predictions are for botulinum toxins, retinoids, anorectics, lipase inhibitors, 5-alpha reductase inhibitors, antiandrogenics, hydroquinones, and tretinoin to 2012
- Which therapy areas are forecast for high-value growth over the next decade
- Which companies are developing novel drugs for aesthetic indications
- What are the unmet needs in the antiageing and image dermatology field
- Which therapy areas are niche market opportunities
- What the future outlook holds for marketed dermatologicals associated with ageing or lifestyle
dissatisfaction
- What the research and development trends are in image dermatology
- Which molecules and compounds are being evaluated with potential indications for
antiageing, aesthetics or lifestyle
- Which are the top prospects for image dermatology over the next decade and to 2020
Plus Many Other Insights, Observations, Assumptions, and Predictions to be Garnered…
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Alopecia Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Lifestyle Disorders Market to 2016 - Limited Pipeline Products and Slow Progress in R&D are Major Concerns
HIV-Associated Lipodystrophy Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Clinical Trial Recruitment in Dermatology - Most Trials Focus on Atopic Dermatitis While Acne Vulgaris Has Highest Patient Numbers
Transdermal Drug Delivery - Technologies, Markets, and Companies
Dermatology Therapeutics Market to 2017 - Alopecia Market is Forecast to Decline Due to Patent Expiry of Finasteride in 2013 and Weak Pipeline
The World Market for Addiction Disorders, 2009–2016, The Future Therapies for Substance Dependence and Impulse Control
Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies
Drug Discovery and Preclinical Molecules by Therapy Area - Innovation Focuses on Stem Cell Therapies and Gene Therapies
Strategic Overview of the Autoimmune Biologics Market
|
|
|
|
